EyePoint Pharmaceuticals, Inc. — Director's Dealing 2018

Nov 16, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2018-11-15

Reporting Person: ROGERS MICHAEL W (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-11-15	Common Stock	M	100000	$1.13	Acquired	112500	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-11-15	Employee Stock Option (right to buy)	$1.13	M	100000	Disposed	2018-11-18	Common Stock (100000)	Direct

Footnotes

F1: Consists of (i) 100,000 shares of common stock, par value $0.001 per share, of EyePoint Pharmaceuticals, Inc. (the "Company") acquired upon exercise of the stock option as described above and (ii) 12,500 shares of common stock of the Company underlying certain deferred stock units ("DSUs") previously awarded to the reporting person, with each DSU representing the right to receive one share of common stock of the Company. These DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986,